A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Hypoxia Clinical Trial

Official title:

A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00495144
• Other study ID #: TH-CR-401
• Status: Completed
• Phase: Phase 1
• First received: June 28, 2007
• Last updated: July 25, 2012
• Start date: June 2007
• Est. completion date: June 2012

Study information

• Verified date: July 2012
• Source: Threshold Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors. The study is designed to establish the safety including the maximum tolerated dose, the pharmacokinetics, and the anti-tumor activity of TH-302.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: June 2012
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years of age

• Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee

• Histologically or cytologically confirmed advanced or metastatic solid malignancy

• Advanced or metastatic solid malignancy previously treated with one or more regimens of chemotherapy or for which no effective therapy is available

• Recovered from toxicities of prior therapy

• Measurable disease by RECIST criteria (at least one target lesion)

• ECOG performance status of 0 or 1

• Life expectancy of at least 3 months

• Acceptable liver function:

• Bilirubin = 1.5 times upper limit of normal

• AST (SGOT) and ALT (SGPT) = 2.5 times upper limit of normal (ULN); if liver metastases are present, then = 5 x ULN is allowed

• Acceptable renal function:

• Serum creatinine = ULN

• Acceptable hematologic status (without hematologic support):

• ANC = 1500 cells/µL

• Platelet count = 100,000/µL

• Hemoglobin = 9.0 g/dL

• Urinalysis: No clinically significant abnormalities

• Acceptable coagulation status:

• PT = 1.3 x ULN

• PTT = 1.3 x ULN

• All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose

Exclusion Criteria:

• Prior treatment with high dose chemotherapy

• Prior radiotherapy to more than 25% of the bone marrow

• New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, or unstable arrhythmia

• Seizure disorders requiring anticonvulsant therapy

• Symptomatic brain metastases (unless previously treated and well controlled for a period of = 3 months)

• Severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the investigator any physiological state leading to hypoxemia

• Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery

• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

• Treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.) or hormones within 4 weeks prior to study entry (6 weeks for nitrosoureas or Mitomycin C)

• Patients who participated in an investigational drug or device study within 28 days prior to study entry

• Known infection with HIV, hepatitis B, or hepatitis C

• Patients who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation (containing solutol and/or propylene glycol)

• Females who are pregnant or breast-feeding

• Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study

• Unwillingness or inability to comply with the study protocol for any reason

Related Conditions & MeSH terms

• Hypoxia
• Tumors

Intervention

Drug:
• TH-302

Locations

Country	Name	City	State
United States	Mary Crowley Cancer Research Centers	Dallas	Texas
United States	Indiana University Simon Cancer Center	Indianapolis	Indiana
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	Mayo Clinic Rochester	Rochester	Minnesota
United States	St. Mary's Medical Center	San Francisco	California
United States	Mayo Clinic Arizona	Scottsdale	Arizona
United States	TGen Drug Development Services	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Threshold Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of TH-302 administered weekly x 3, repeated every 4 weeks in patients with advanced solid tumors
Secondary	To establish the pharmacokinetics of intravenously administered TH-302
Secondary	To assess the anti-tumor activity of TH-302 as measured by objective response and duration of response

External Links

•   Threshold Pharmaceuticals Company Website